Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Monday, 03 / 08 / 2021

Welcome to JCTH


Impact of Liver Injury in COVID-19 Patients: Single-center Retrospective Cohort Analysis

Jiten Desai,*, Upenkumar Patel, Shiva ArjunKristen FarrajKevin YeroushalmiSandra Gomez PazJaehyuck ImAndres CastilloRajmohan Rammohan and Paul Mustacchia

Department of Internal Medicine, Nassau University Medical Center, East Meadow, NY, USA
*Correspondence to: Jiten Desai, Department of Internal Medicine, Nassau University Medical Center, 2201 Hempstead Turnpike, East Meadow, NY 11554, USA. Tel: +1-516-296-2253, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2020;8(4):476-478 DOI: 10.14218/JCTH.2020.00075
Received: August 6, 2020 Accepted: October 8, 2020 Published online: October 23, 2020


Coronavirus disease 2019 (COVID-19) has become a serious threat to global public health. Unfortunately, to date, there are no specific vaccines or targeted drugs, and the number of patients with positivity for systemic acute respiratory syndrome-novel coronavirus-2 infection is growing worldwide.1 Patients with COVID-19 may be at risk for liver injury, but the mechanism and clinical significance of injury remains unclear. Proposed mechanisms include direct virus-induced insults, immune-mediated damage (due to excessive inflammatory response), and drug-induced injury. COVID-19-related liver dysfunction is now gaining widespread attention; however, liver injury’s impact on the outcome of COVID-19 patients is not clearly understood. We have evaluated the impact of liver insults on the hospitalization outcome of COVID-19 patients admitted to a suburban New York safety-net hospital and would like to share our preliminary results in a Letter to the Editor instead of an Original Article forrapid dissemination to the worldwide audience.

In our retrospective, unmatched, single-center analysis, we have identified the first 639 confirmed COVID-19 patients (ages ≥18 years) admitted to our facility from March 2020 to May 2020. Elevated liver-related enzymes [serum alanine aminotransferase (commonly referred to as ALT) >40 U/L, aspartate aminotransferase (commonly referred to as AST) >40 U/L, or alkaline phosphatase (commonly referred to as ALP) >120] were used to stratify patients with or without liver injury. The primary outcome was all-cause in-hospital mortality; other in-patient outcomes, including cardiac arrest, acute respiratory distress syndrome, arrhythmia, shock, and intubation rate, were also measured. The Pearson’s chi-square test and Student’s t-test were used for evaluating categorical and continuous variables, respectively. A two-step hierarchical multivariate regression model was performed to assess the risk of in-patient mortality and other hospitalization outcomes after adjusting for baseline characteristics and comorbidities. All statistical analyses were performed using SPSS® Corp. Version 22 (Armonk, NY, USA). This analysis was approved by the Institutional Review Board (IRB) of Nassau Health Care Corporation (NHCC) at Nassau University Medical Center (NUMC), under IRB reference # 20-277.


Journal of Clinical and Translational Hepatology 2020 vol. 8, 476-478  [ Html  ] [ PDF Full-text ]

© The Authors 2020. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.


You are here: Home Vol 8 Issue 4 Abstract